Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Mostafa, Ahmed A ^a   Codner, Dianne ^a   Hirasawa, Kensuke ^a   Komatsu, Yumiko ^a   Young, Matthew N ^a   Steimle, Viktor ^b   Drover, Sheila ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLASS II TRANSACTIVATOR PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; SMALL INTERFERING RNA; STAT1 PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN; CELL STRAIN BT 474; CELL STRAIN MDA MB 231; CELL STRAIN SK BR 3; CELL STRAIN T47D,; CONTROLLED STUDY; DOWN REGULATION; ERALPHA GENE; ESR1 GENE; GENE; GENE CONTROL; GENE SILENCING; GENETIC TRANSFECTION; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; MCF 7 CELL LINE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR ESCAPE;

ANALYSIS OF VARIANCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON-GAMMA; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR ESCAPE;

EID: 84900319543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087377     Document Type: Article

References (86)

1. Armstrong TD, Clements VK, Ostrand-Rosenberg S (1998) MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol 160: 661-666. (Pubitemid 28049305)
2. Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS (2003) Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 33: 1183-1192. (Pubitemid 36609136)
3. Accolla RS, Frangione V, De Lerma Barbaro A, Mortara L (2010) New strategies of mammary cancer vaccination. Breast Journal 16: S42-S44.
4. Accolla RS, Tosi G (2012) Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: The key issue for development of antitumor vaccines. J Transl Med 10: 154.
5. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, et al. (1984) Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci U S A 81: 4917-4921. (Pubitemid 14066225)
6. Jabrane-Ferrat N, Faille A, Loiseau P, Poirier O, Charron D, et al. (1990) Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines. Int J Cancer 45: 1169-1176. (Pubitemid 20201592)
7. Martins I, Deshayes F, Baton F, Forget A, Ciechomska I, et al. (2007) Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Eur J Immunol 37: 788-797. (Pubitemid 46916945)
8. Warabi M, Kitagawa M, Hirokawa K (2000) Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: Immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas. Pathol Res Pract 196: 807-815. (Pubitemid 32037238)
9. Bustin SA, Li SR, Phillips S, Dorudi S (2001) Expression of HLA class II in colorectal cancer: Evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumour Biol 22: 294-298. (Pubitemid 32823947)
10. Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, et al. (1995) Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur J Immunogenet 22: 299-310.
11. Oldford SA, Robb JD, Watson PH, Drover S (2004) HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. Int J Cancer 112: 399-406. (Pubitemid 39390603)
12. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, et al. (2006) Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol 18: 1591-1602. (Pubitemid 44605580)
13. Cabrera T, Angustias FM, Sierra A, Garrido A, Herruzo A, et al. (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50: 127-134. (Pubitemid 26337114)
14. Calabro A, Beissbarth T, Kuner R, Stojanov M, Benner A, et al. (2009) Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116: 69-77.
15. Sedlak J, Speiser P, Zeillinger R, Krugluger W, Wiltschke C, et al. (1992) Cytokine (IFN-alpha, IFN-gamma, IL-1-alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human breast cancer cell lines. Neoplasma 39: 269-272.
16. Rohn W, Tang LP, Dong Y, Benveniste EN (1999) IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene. J Immunol 162: 886-896. (Pubitemid 29035413)
17. Tzortzakaki E, Spilianakis C, Zika E, Kretsovali A, Papamatheakis J (2003) Steroid receptor coactivator 1 links the steroid and interferon gamma response pathways. Mol Endocrinol 17: 2509-2518. (Pubitemid 37542213)
18. Bernard DJ, Maurizis JC, Chassagne J, Chollet P, Plagne R (1986) Effect of prolactin on class II HLA antigen expression by MCF7 cell line. Anticancer Res 6: 79-83.
19. Tabibzadeh SS, Sivarajah A, Carpenter D, Ohlsson-Wilhelm BM, Satyaswaroop PG (1990) Modulation of HLA-DR expression in epithelial cells by interleukin 1 and estradiol-17 beta. J Clin Endocrinol Metab 71: 740-747.
20. Maudsley DJ (1991) Role of oncogenes in the regulation of MHC antigen expression. Biochem Soc Trans 19: 291-296.
21. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B (1997) Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16: 2851-2860. (Pubitemid 27226221)
22. Setterblad N, Peterlin BM, Andersson G (1997) Role of the X2 box in activated transcription from the DRA promoter in B cells. Immunogenetics 46: 318-325. (Pubitemid 27321044)
23. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM (1999) CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 10: 143-151. (Pubitemid 29115620)
24. Muhlethaler-Mottet A, Krawczyk M, Masternak K, Spilianakis C, Kretsovali A, et al. (2004) The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA. J Biol Chem 279: 40529-40535. (Pubitemid 39287644)
25. Ting JP, Trowsdale J (2002) Genetic control of MHC class II expression. Cell 109 Suppl: S21-S33. (Pubitemid 34457849)
26. van der Stoep N, Quinten E, van den Elsen PJ (2002) Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: Identification of a novel regulatory region in the 5′-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes. J Immunol 169: 5061-5071. (Pubitemid 35217175)
27. Otten LA, Steimle V, Bontron S, Mach B (1998) Quantitative control of MHC class II expression by the transactivator CIITA. Eur J Immunol 28: 473-478. (Pubitemid 28101722)
28. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, et al. (1998) A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20: 273-277. (Pubitemid 28507672)
29. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, et al. (2000) Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 20: 6051-6061. (Pubitemid 30613053)
30. Hake SB, Tobin HM, Steimle V, Denzin LK (2003) Comparison of the transcriptional regulation of classical and non-classical MHC class II genes. Eur J Immunol 33: 2361-2371. (Pubitemid 37138968)
31. Steimle V, Otten LA, Zufferey M, Mach B (1993) Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75: 135-146. (Pubitemid 23306027)
32. Reith W, Mach B (2001) The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19: 331-373. 10.1146/annurev.immunol.19.1.331. (Pubitemid 32368039)
33. Muhlethaler-Mottet A, Di BW, Otten LA, Mach B (1998) Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8: 157-166. (Pubitemid 28123743)
34. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-24. (Pubitemid 34246317)
35. Ahmed CM, Johnson HM (2006) IFN-gamma and its receptor subunit IFNGR1 are recruited to the IFN-gamma-activated sequence element at the promoter site of IFN-gamma-activated genes: Evidence of transactivational activity in IFNGR1. J Immunol 177: 315-321.
36. Sadzak I, Schiff M, Gattermeier I, Glinitzer R, Sauer I, et al. (2008) Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain. Proc Natl Acad Sci U S A 105: 8944-8949.
37. Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7: 497-508. (Pubitemid 46068961)
38. Ramsauer K, Sadzak I, Porras A, Pilz A, Nebreda AR, et al. (2002) p38 MAPK enhances STAT1-dependent transcription independently of ser-727 phosphorylation. Proc Natl Acad Sci U S A 99: 12859-12864.
39. Giroux M, Schmidt M, Descoteaux A (2003) IFN-gamma-induced MHC class II expression: Transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-alpha. J Immunol 171: 4187-4194. (Pubitemid 37238695)
40. Hardy PO, Diallo TO, Matte C, Descoteaux A (2009) Roles of phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase in the regulation of protein kinase C-alpha activation in interferon-gamma-stimulated macrophages. Immunology 128: e652-660.
41. Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86: 225-230.
42. Andersen P, Pedersen MW, Woetmann A, Villingshoj M, Stockhausen MT, et al. (2008) EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer 122: 342-349. (Pubitemid 350234720)
43. Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17: 309-317.
44. Adamski J, Ma Z, Nozell S, Benveniste EN (2004) 17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol 18: 1963-1974. (Pubitemid 39006501)
45. Adamski J, Benveniste EN (2005) 17beta-estradiol activation of the c-jun N-terminal kinase pathway leads to down-regulation of class II major histocompatibility complex expression. Mol Endocrinol 19: 113-124. (Pubitemid 40065963)
46. Pietras RJ, Marquez-Garban DC (2007) Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 13: 4672-4676. (Pubitemid 47294772)
47. Tonetti DA, Rubenstein R, DeLeon M, Zhao H, Pappas SG, et al. (2003) Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 87: 47-55. (Pubitemid 37421338)
48. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ (1997) Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45: 607-617. (Pubitemid 27506136)
49. Filardo EJ (2002) Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80: 231-238.
50. Morris AC, Beresford GW, Mooney MR, Boss JM (2002) Kinetics of a gamma interferon response: Expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 22: 4781-4791. (Pubitemid 34620413)
51. Morrow AN, Schmeisser H, Tsuno T, Zoon KC (2011) A novel role for IFN-stimulated gene factor 3II in IFN-gamma signaling and induction of antiviral activity in human cells. J Immunol 186: 1685-1693.
52. O'Donnell PW, Haque A, Klemsz MJ, Kaplan MH, Blum JS (2004) Cutting edge: Induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells is STAT1-dependent but CIITA-independent. J Immunol 173: 731-735. (Pubitemid 38924246)
53. Aka JA, Lin SX (2012) Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7. PLoS One 7: e31532.
54. Renoir JM (2012) Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. Steroids 77: 1249-1261.
55. Matthews J, Gustafsson JA (2006) Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 4: e016.
56. Zhao C, Matthews J, Tujague M, Wan J, Strom A, et al. (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67: 3955-3962. (Pubitemid 46762185)
57. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lakins J, Lupu R (2000) Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep 7: 157-167.
58. Sastre-Serra J, Nadal-Serrano M, Pons DG, Valle A, Oliver J, et al. (2012) The effects of 17beta-estradiol on mitochondrial biogenesis and function in breast cancer cell lines are dependent on the ERalpha/ERbeta ratio. Cell Physiol Biochem 29: 261-268.
59. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, et al. (2007) Estrogen receptors: How do they signal and what are their targets. Physiol Rev 87: 905-931. (Pubitemid 47084672)
60. Zika E, Fauquier L, Vandel L, Ting JP (2005) Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression. Proc Natl Acad Sci U S A 102: 16321-16326. (Pubitemid 41688912)
61. Wright KL, Ting JP (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27: 405-412. (Pubitemid 44216195)
62. Holling TM, van Eggermond MC, Jager MJ, van den Elsen PJ (2006) Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol 72: 1570-1576. (Pubitemid 44666742)
63. Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, et al. (2003) Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol 170: 4980-4985. (Pubitemid 36554727)
64. Londhe P, Zhu B, Abraham J, Keller C, Davie J (2012) CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. Int J Cancer 131: e437-448.
65. Shi B, Vinyals A, Alia P, Broceno C, Chen F, et al. (2006) Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription implication of CIITA in tumor and metastasis development. Int J Biochem Cell Biol 38: 544-562. (Pubitemid 43117579)
66. Truax AD, Thakkar M, Greer SF (2012) Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells. PLoS One 7: e36013.
67. Lacroix M (2008) Persistent use of "false" cell lines. Int J Cancer 122: 1-4.
68. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104: 13-19. (Pubitemid 46976633)
69. Zhou Q, Shaw PG, Davidson NE (2009) Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. Endocr Relat Cancer 16:319-323.
70. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, et al. (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23: 1724-1736. (Pubitemid 38445164)
71. Zhou Q, Shaw PG, Davidson NE (2009) Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat 117: 443-451.
72. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D (2007) Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 13: 7029-7036. (Pubitemid 350276884)
73. Duong V, Licznar A, Margueron R, Boulle N, Busson M, et al. (2006) ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 25: 1799-1806.
74. Zhu Y, Singh B, Hewitt S, Liu A, Gomez B, et al. (2006) Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays. Int J Oncol 28: 67-76.
75. Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, et al. (2011) Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res 13: R111.
76. Schwartz JL, Shajahan AN, Clarke R (2011) The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int J Breast Cancer 2011: 912102.
77. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, et al. (2012) STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res 14: R16.
78. Lee YJ, Benveniste EN (1996) Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes. J Immunol 157: 1559-1568.
79. Piskurich JF, Linhoff MW, Wang Y, Ting JP (1999) Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol 19: 431-440. (Pubitemid 29018445)
80. Kennedy AM, Shogren KL, Zhang M, Turner RT, Spelsberg TC, et al. (2005) 17beta-estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on src kinase activity. Endocrinology 146: 201-207. (Pubitemid 40051740)
81. Gough DJ, Sabapathy K, Ko EY, Arthur HA, Schreiber RD, et al. (2007) A novel c-jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem 282: 938-946. (Pubitemid 47076563)
82. Johnson HM, Noon-Song E, Ahmed CM (2011) Controlling nuclear jaks and stats for specific gene activation by ifn gamma and other cytokines: A possible steroid-like connection. J Clin Cell Immunol 2: 1000112.
83. Lampson LA, Levy R (1980) Two populations of ia-like molecules on a human B cell line. J Immunol 125: 293-299. (Pubitemid 10040437)
84. Camacho-Carvajal MM, Klingler S, Schnappauf F, Hake SB, Steimle V (2004) Importance of class II transactivator leucine-rich repeats for dominant-negative function and nucleo-cytoplasmic transport. Int Immunol 16: 65-75. (Pubitemid 38054628)
85. Spurrell DR, Oldford SA, Frost T, Larsen B, Codner D, et al. (2004) Discordant expression of HLA class II-associated co-chaperones and HLA-DRB alleles in cultured fibroblast-like synoviocytes. Hum Immunol 65: 1516-1529. (Pubitemid 39643232)
86. Kaur S, Uddin S, Platanias LC (2005) The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res 25: 780-787. (Pubitemid 43068489)